Similarly, NKG2D has been shown to increase expression on GBM following irradiation; mice bearing glioma tumors had improved survival with combination irradiation and CAR T therapy targeting NKG2D, compared to monotherapy alone [104]. Here, KLRK1 is linked to central nervous system cancer.